Savara (SVRA) Other Non Operating Income (2010 - 2026)
Savara (SVRA) posted quarterly Other Non Operating Income of -$216000.0 for Q1 2026, down 460.0% year-over-year from $60000.0 in Q1 2025, and down 118.26% quarter-over-quarter from $1.2 million in Q4 2025.
Analysis
Savara (SVRA) Other Non Operating Income (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Other Non Operating Income for 17 consecutive years, with -$216000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income fell 460.0% year-over-year to -$216000.0; the TTM figure through Mar 2026 stood at $2.2 million (down 79.69% YoY), while the FY2025 annual figure was $4.7 million, down 35.61% from the prior year.
- Other Non Operating Income retreated to -$216000.0 in Q1 2026 per SVRA's latest filing, from $1.2 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7.5 million in Q4 2024 and bottomed at -$254000.0 in Q1 2022.
- Historically, Other Non Operating Income has averaged $916941.2 across 5 years, with a median of $60000.0 in 2025.
- Annual changes were most pronounced in 2024 — Other Non Operating Income soared 210800.0% — and 2026, when it plunged 460.0%.
- Savara's Other Non Operating Income stood at -$40000.0 in 2022, then jumped by 3927.5% to $1.5 million in 2023, then surged by 388.63% to $7.5 million in 2024, then slumped by 84.19% to $1.2 million in 2025, then slumped by 118.26% to -$216000.0 in 2026.
- Business Quant data shows SVRA's Other Non Operating Income at -$216000.0 in Q1 2026, $1.2 million in Q4 2025, and $146000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 737,000.00 |
| Mar 31, 2026 | 1.71 Mn |
| Dec 31, 2025 | 1.18 Mn |
| Sep 30, 2025 | 694,000.00 |
| Jun 30, 2025 | 1.04 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.11 Mn |
| Jun 30, 2024 | 947,000.00 |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.53 Mn |
| Sep 30, 2023 | 1.45 Mn |
| Jun 30, 2023 | 778,000.00 |
| Mar 31, 2023 | 1.56 Mn |
| Dec 31, 2022 | 575,000.00 |
| Sep 30, 2022 | 149,000.00 |
| Jun 30, 2022 | 219,000.00 |
| Mar 31, 2022 | -254,000.00 |
| Dec 31, 2021 | -671,000.00 |
| Sep 30, 2021 | -574,000.00 |